InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,482.87
(
0.09%
)
US TECH 100
19,304.80
(
0.47%
)
Dow Jones
39,164.06
(
0.09%
)
Brent Oil
85.61
(
0.22%
)
Bitcoin
61,591.80
(
-0.03%
)
Post# of 252412
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119944
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: ghmm post# 207148

Tuesday, 12/20/2016 10:04:01 AM

Tuesday, December 20, 2016 10:04:01 AM

Post# of 252412

If FoBs follow the 20% or so discount to the branded product that would still seem attractive pricing potential for HIF drugs with the added benefit of being Oral, maybe alleviate the need for Iron and possible safety advantage.

If there are multiple FoBs for a given drug in a given market, the price erosion will likely be much more than 20%. Look at the US market for Lovenox as an example of how bad things can get with multiple players.

Nevertheless, I'm not opining that the HIF drugs are a bad business proposition.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up